Radio Jamaica Limited (JMSE:RJR)
Jamaica · Delayed Price · Currency is JMD 1.270
-0.020 (-1.55%)
At close: Aug 4, 2025
Sage Therapeutics Income Statement
Financials in millions JMD. Fiscal year is April - March.
Millions JMD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2016 - 2020 |
| 5,400 | 5,491 | 5,437 | 5,711 | 5,192 | 5,593 | Upgrade | |
Revenue Growth (YoY) | 0.23% | 1.00% | -4.81% | 9.99% | -7.16% | 2.00% | Upgrade |
Cost of Revenue | 3,019 | 2,948 | 2,863 | 2,509 | 2,287 | 2,586 | Upgrade |
Gross Profit | 2,381 | 2,543 | 2,574 | 3,202 | 2,905 | 3,006 | Upgrade |
Selling, General & Admin | 2,282 | 2,309 | 1,995 | 2,135 | 2,086 | 2,098 | Upgrade |
Other Operating Expenses | 785.64 | 690.88 | 741.39 | 636.53 | 560.06 | 827.37 | Upgrade |
Operating Expenses | 3,181 | 3,113 | 2,737 | 2,771 | 2,647 | 2,926 | Upgrade |
Operating Income | -799.97 | -570.35 | -162.97 | 430.35 | 258.48 | 80.71 | Upgrade |
Interest Expense | -55.02 | -49.81 | -52.93 | -47.9 | -51.05 | -50.83 | Upgrade |
Interest & Investment Income | 30.91 | 30.91 | 15.32 | 6.12 | 3.1 | 6.09 | Upgrade |
Earnings From Equity Investments | -24.53 | -24.53 | -0.12 | -12.29 | -0.78 | -0.15 | Upgrade |
Currency Exchange Gain (Loss) | -11.83 | -11.83 | -17.79 | 5.54 | -2.04 | 0.36 | Upgrade |
EBT Excluding Unusual Items | -860.44 | -625.61 | -218.5 | 381.83 | 207.7 | 36.18 | Upgrade |
Merger & Restructuring Charges | - | - | -19.9 | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -13.11 | -13.11 | -15.01 | - | 4.05 | 0.38 | Upgrade |
Gain (Loss) on Sale of Assets | 9.29 | 10.12 | 2.2 | 26.93 | 19.94 | 2.91 | Upgrade |
Asset Writedown | 61.65 | 61.65 | 51.61 | - | - | - | Upgrade |
Other Unusual Items | - | - | 444.2 | - | - | - | Upgrade |
Pretax Income | -802.6 | -566.95 | 244.61 | 408.76 | 231.69 | 39.47 | Upgrade |
Income Tax Expense | -79.28 | -38.2 | -5.73 | 67.07 | 61.03 | 1.91 | Upgrade |
Net Income | -723.32 | -528.75 | 250.34 | 341.69 | 170.66 | 37.56 | Upgrade |
Net Income to Common | -723.32 | -528.75 | 250.34 | 341.69 | 170.66 | 37.56 | Upgrade |
Net Income Growth | - | - | -26.73% | 100.22% | 354.37% | - | Upgrade |
Shares Outstanding (Basic) | 2,968 | 2,999 | 2,598 | 2,398 | 2,398 | 2,398 | Upgrade |
Shares Outstanding (Diluted) | 2,968 | 2,999 | 2,598 | 2,398 | 2,398 | 2,398 | Upgrade |
Shares Change (YoY) | 13.18% | 15.42% | 8.36% | - | - | - | Upgrade |
EPS (Basic) | -0.24 | -0.18 | 0.10 | 0.14 | 0.07 | 0.02 | Upgrade |
EPS (Diluted) | -0.24 | -0.18 | 0.10 | 0.14 | 0.07 | 0.02 | Upgrade |
EPS Growth | - | - | -32.39% | 100.22% | 354.39% | - | Upgrade |
Free Cash Flow | -757.74 | -513.19 | -648.03 | 4.81 | 363.58 | -32.44 | Upgrade |
Free Cash Flow Per Share | -0.26 | -0.17 | -0.25 | 0.00 | 0.15 | -0.01 | Upgrade |
Dividend Per Share | - | - | 0.036 | 0.040 | - | 0.020 | Upgrade |
Dividend Growth | - | - | -10.00% | - | - | - | Upgrade |
Gross Margin | 44.09% | 46.31% | 47.34% | 56.06% | 55.95% | 53.75% | Upgrade |
Operating Margin | -14.82% | -10.39% | -3.00% | 7.54% | 4.98% | 1.44% | Upgrade |
Profit Margin | -13.40% | -9.63% | 4.61% | 5.98% | 3.29% | 0.67% | Upgrade |
Free Cash Flow Margin | -14.03% | -9.35% | -11.92% | 0.08% | 7.00% | -0.58% | Upgrade |
EBITDA | -492.33 | -263.24 | 83.95 | 657.61 | 486.78 | 332.81 | Upgrade |
EBITDA Margin | -9.12% | -4.79% | 1.54% | 11.52% | 9.38% | 5.95% | Upgrade |
D&A For EBITDA | 307.64 | 307.1 | 246.92 | 227.26 | 228.3 | 252.1 | Upgrade |
EBIT | -799.97 | -570.35 | -162.97 | 430.35 | 258.48 | 80.71 | Upgrade |
EBIT Margin | -14.82% | -10.39% | -3.00% | 7.54% | 4.98% | 1.44% | Upgrade |
Effective Tax Rate | - | - | - | 16.41% | 26.34% | 4.85% | Upgrade |
Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.